Navigation Links
Savient Pharmaceuticals to Present at the Canaccord Genuity 32nd Annual Growth Conference
Date:8/6/2012

EAST BRUNSWICK, N.J., Aug. 6, 2012 /PRNewswire/ -- Savient Pharmaceuticals, Inc. (NASDAQ: SVNT) today announced that Lou Ferrari, President and Chief Executive Officer, will present at the Canaccord Genuity 32nd Annual Growth Conference on Thursday, August 16, 2012 at 1:00 PM Eastern Time.  The conference will be held at the InterContinental Hotel in Boston, MA.

A live webcast of the presentation can be accessed through the investor relations section of the Company's website at www.savient.com.  Following the live presentation, a replay of the webcast will be available on the Company's website for 30 days.

ABOUT SAVIENT PHARMACEUTICALS, INC.Savient Pharmaceuticals, Inc. is a specialty biopharmaceutical company focused on developing and commercializing KRYSTEXXA® (pegloticase) for the treatment of chronic gout in adult patients refractory to conventional therapy. Savient has exclusively licensed worldwide rights to the technology related to KRYSTEXXA and its uses from Duke University ("Duke") and Mountain View Pharmaceuticals, Inc. ("MVP").  Duke developed the recombinant uricase enzyme and MVP developed the PEGylation technology used in the manufacture of KRYSTEXXA. MVP and Duke have been granted U.S. and foreign patents disclosing and claiming the licensed technology and, in addition, Savient owns or co-owns U.S. and foreign patents and patent applications, which collectively form a broad portfolio of patents covering the composition, manufacture and methods of use and administration of KRYSTEXXA.  Savient also manufactures and supplies Oxandrin® (oxandrolone tablets, USP) CIII in the U.S. For more information, please visit the Company's website at www.savient.com.

SVNT – GContact:Mary ColemanCarney Noensie Savient Pharmaceuticals, Inc.Burns McClellan  information@savient.comcnoensie@burnsmc.com(732) 418-93(212) 213-0006


'/>"/>
SOURCE Savient Pharmaceuticals, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. Savient Pharmaceuticals Adopts Stockholder Rights Plan
2. Savient Pharmaceuticals Receives Favorable Decision In Tang Capital Litigation
3. Savient Pharmaceuticals to Hold Second Quarter 2012 Financial Results Conference Call on Wednesday, August 8, 2012
4. Savient Pharmaceuticals Announces CEO Appointment and Reorganization Plan to Drive Long-Term Growth
5. Savient Pharmaceuticals to Present at the Bank of America Merrill Lynch 2012 Health Care Conference
6. Savient Pharmaceuticals to Hold First Quarter 2012 Financial Results Conference Call on Wednesday, May 9, 2012
7. TWi Pharmaceuticals Announces Positive Phase IIb Clinical Trial Results of AC-201 in Patients with Type 2 Diabetes.
8. OncoGenex Pharmaceuticals, Inc. Reports Second Quarter and First-Half 2012 Financial Results and Reviews Clinical Development Highlights for Custirsen and OGX-427
9. Cumberland Pharmaceuticals Reports Second Quarter 2012 Financial Results
10. Arena Pharmaceuticals to Host Business and Financial Update Conference Call and Webcast on Thursday, August 9
11. Global Pharmaceuticals Market 2011-2015
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/6/2017)... CHICAGO , May 5, 2017  May is ... of one of the most important methods to prevent ... to the Centers for Disease Control and Prevention, undetected ... stroke. 1 Omron, the global leader in personal ... on the elimination of heart attack and stroke and ...
(Date:5/4/2017)... LAWRENCE, Mass. and SAN DIEGO ... of Obstetricians and Gynecologists (ACOG) 2017 Annual Clinical and ... of single-use, self-contained, illuminating medical devices, today announced the ... size of its OfficeSPEC and ER-SPEC ... large, the addition of extra-small and extra-large sizes makes ...
(Date:5/3/2017)... 2017  Kalorama Information notes that transplant diagnostics ... year and this is projected to continue to ... (HSCT) or bone marrow transplants require histocompatibility between ... for this task. This according to a new ... The various PCR-based methodologies, Sanger sequencing and NGS ...
Breaking Medicine Technology:
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... ... met this week to review more than eighty-nine grant submissions all vying ... emerging young scientists in the Parkinson’s field.     , The American Parkinson Disease Association ...
(Date:5/26/2017)... ... , ... Amir Qureshi, MD is the first physician in Arkansas to implant ... The Nuvectra™ Algovita SCS System has been FDA approved as a treatment option for ... to introduce the most powerful SCS system and the only stretchable lead on the ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... ... premium delicatessen foods, is sharing bold recipes for Memorial Day entertaining that are ... menus. , “Boar’s Head fresh sliced meats and cheeses featured in these ...
(Date:5/26/2017)... (PRWEB) , ... May 26, 2017 , ... After raising ... Antzy Top gadget will continue to be available at a discounted crowdfunding price on ... with stress wherever they are, I also wanted to bring a fidget toy to ...
(Date:5/26/2017)... ... ... Lowe acts as host and helps educate and inform the public using the “Informed” ... reconnect with America as it explores some of the best places to hike and ... inventive new place for a family vacation, and have discovered hiking. Many will agree ...
Breaking Medicine News(10 mins):